ArticleTechnology in cancer research & treatment
Gastric Cancer Heterogeneity and Clinical Outcomes.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Analysis of the Matrix Metalloproteinases Family Profile in Gastric Cancer Suggests Key Matrix Metalloproteinases for Tumor Development and Their Clinical Impact.Molecular carcinogenesis · 2026Article
- Article
- Dissecting molecular heterogeneity in primary gastric cancer by IGFBP7-related analysis.Journal of translational medicine · 2026Article
- GXYLT2 serves as a prognostic biomarker and is associated with β-catenin activation and gastric cancer aggressiveness.Genes & diseases · 2026Article
- Evolving Molecular Subtypes of Gastric Cancer: From Past Classifications to Present Consensus and Future Directions for Precision Therapy.Journal of gastric cancer · 2026Review
- METTL9 as a protein biomarker predicts the prognosis and immunotherapy response of skin-cutaneous melanoma.Annals of medicine and surgery (2012) · 2025Article
- The effect of USP17 knockdown on autophagic ferroptosis in gastric cancer by regulating the BNIP3-NCOA4-FTH1 axis.Journal of molecular histology · 2025Article
- Transcriptomic Profiling of Gastric Cancer Reveals Key Biomarkers and Pathways via Bioinformatic Analysis.Genes · 2025Article
- Exploring the Shared miRNA-mRNA Signature Network Between Helicobacter pylori Infection and Gastric Cancer: A Comparative Study.Current microbiology · 2025Article
- A hybrid multi-instance learning-based identification of gastric adenocarcinoma differentiation on whole-slide images.Biomedical engineering online · 2025Article
- Clinical characteristics, prognosis, and nomogram for upper esophageal cancer: a SEER database analysis.Scientific reports · 2025Article
- Low GCNT2/I-Branching Glycan Expression Is Associated with Bladder Cancer Aggressiveness.Biomedicines · 2025Article
- Herbs and their Active Constituents for Gastric Cancer and Related Problems - Preclinical and Clinical Studies.Current protein & peptide science · 2025Review
- Hypomethylation ofFrontiers in immunology · 2025Article
- Integrative single-cell atlas unveils heterogeneity and prognostic value of cancer-associated fibroblasts in gastric cancer.Frontiers in oncology · 2025Article
- Stimulative piezoelectric nanofibrous scaffolds for enhanced small extracellular vesicle production in 3D cultures.Biomaterials science · 2024Article
- Single-cell sequencing analysis revealed that WDR72 was a novel cancer stem cells related gene in gastric cancer.Heliyon · 2024Article
- Targeting cell surface glucose-regulated protein 94 in gastric cancer with an anti-GRP94 human monoclonal antibody.BMB reports · 2024Article
- A Rare Case of Primary Gastric Signet Ring Cell Carcinoma: a Review of Guidelines for the Management of Gastric Cancer.Indian journal of surgical oncology · 2024Article
- Machine learning-based radiomics score improves prognostic prediction accuracy of stage II/III gastric cancer: A multi-cohort study.World journal of gastrointestinal surgery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric adenocarcinoma is a highly aggressive disease with poor overall survival. The aggressive nature of this disease is in part due to the high intra and inter tumoral heterogeneity and also due to the late diagnosis at presentation. Once progression occurs, treatment is more difficult due to the adaptation of tumors, which acquires resistance to commonly used chemotherapeutics. In this report, using publicly available data sets and pathway analysis, we highlight the vast heterogeneity of gastric cancer by investigating genes found to be significantly perturbed. We found several upregulated genes in the diffuse gastric cancer subtypes share similarity to gastric cancer as a whole which can be explained by the increase in this subtype of gastric cancer throughout the world. We report significant downregulation of genes that are underrepresented within the literature, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.